ATE333895T1 - Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4 - Google Patents

Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4

Info

Publication number
ATE333895T1
ATE333895T1 AT95908741T AT95908741T ATE333895T1 AT E333895 T1 ATE333895 T1 AT E333895T1 AT 95908741 T AT95908741 T AT 95908741T AT 95908741 T AT95908741 T AT 95908741T AT E333895 T1 ATE333895 T1 AT E333895T1
Authority
AT
Austria
Prior art keywords
antibodies against
humanized antibodies
adhesion molecule
leukocyte adhesion
molecule vla
Prior art date
Application number
AT95908741T
Other languages
German (de)
English (en)
Inventor
Mary M Bendig
Olivier J Leger
Jose Saldanha
Tarran S Jones
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE333895T1 publication Critical patent/ATE333895T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95908741T 1994-01-25 1995-01-25 Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4 ATE333895T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25

Publications (1)

Publication Number Publication Date
ATE333895T1 true ATE333895T1 (de) 2006-08-15

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95908741T ATE333895T1 (de) 1994-01-25 1995-01-25 Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4

Country Status (21)

Country Link
EP (2) EP0804237B8 (cg-RX-API-DMAC7.html)
JP (5) JP4115517B2 (cg-RX-API-DMAC7.html)
KR (1) KR100367948B1 (cg-RX-API-DMAC7.html)
CN (1) CN1211123C (cg-RX-API-DMAC7.html)
AT (1) ATE333895T1 (cg-RX-API-DMAC7.html)
AU (1) AU703152B2 (cg-RX-API-DMAC7.html)
CA (1) CA2182013C (cg-RX-API-DMAC7.html)
DE (2) DE122006000043I1 (cg-RX-API-DMAC7.html)
DK (2) DK0804237T3 (cg-RX-API-DMAC7.html)
ES (2) ES2270425T3 (cg-RX-API-DMAC7.html)
FI (1) FI117509B (cg-RX-API-DMAC7.html)
FR (1) FR06C0024I2 (cg-RX-API-DMAC7.html)
HU (1) HU220799B1 (cg-RX-API-DMAC7.html)
LU (1) LU91271I2 (cg-RX-API-DMAC7.html)
MX (1) MX9602971A (cg-RX-API-DMAC7.html)
NL (1) NL300238I2 (cg-RX-API-DMAC7.html)
NO (3) NO319867B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ279730A (cg-RX-API-DMAC7.html)
PL (1) PL181827B1 (cg-RX-API-DMAC7.html)
PT (1) PT804237E (cg-RX-API-DMAC7.html)
WO (1) WO1995019790A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
ATE161730T1 (de) * 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU7348798A (en) * 1997-05-09 1998-12-08 John P. Robarts Research Institute, The Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP2065050A1 (en) * 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CA2370814C (en) 1999-04-22 2010-07-06 Biogen, Inc. Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ300710B6 (cs) 1999-06-01 2009-07-22 Biogen Idec Ma Inc. Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2140881B1 (en) * 1999-12-16 2013-04-17 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｖｌａ-1에 대한 항체들
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
US20040009169A1 (en) * 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
MXPA05006384A (es) * 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
EP1827491A4 (en) * 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
US20070122404A1 (en) * 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AR067011A1 (es) * 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
EP2221325B1 (en) 2007-12-13 2014-04-16 Tokuyama Corporation Photochromic curable composition
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
MX338969B (es) 2009-03-20 2016-05-06 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20140161794A1 (en) 2010-04-16 2014-06-12 Biogen Idec Ma Inc. Anti-vla-4 antibodies
ES2646717T3 (es) 2011-05-02 2017-12-15 Millennium Pharmaceuticals, Inc. Formulación para anticuerpo anti- 4 7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
WO2018091729A2 (en) 2016-11-21 2018-05-24 Zaklady Farmaceutyczne Polpharma Sa Aqueous pharmaceutical formulations
CN110997714B (zh) * 2017-02-17 2024-05-03 赛诺菲 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
EP4284947A1 (en) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL95501A (en) * 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
CA2129637C (en) * 1992-02-12 1999-05-04 Roy R. Lobb Treatment for inflammatory bowel disease
ATE182625T1 (de) * 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
NO2017040I2 (no) 2018-08-28
NZ279730A (en) 1998-04-27
CN1211123C (zh) 2005-07-20
EP1759709B1 (en) 2013-02-27
DE122006000043I1 (de) 2007-02-15
NO2006008I1 (no) 2006-08-07
NO2006008I2 (no) 2009-06-15
EP1759709A1 (en) 2007-03-07
DE69535133D1 (de) 2006-09-07
FI117509B (fi) 2006-11-15
HU9602019D0 (en) 1996-09-30
MX9602971A (es) 1998-01-31
FI962958L (fi) 1996-09-24
JP5487382B2 (ja) 2014-05-07
NL300238I1 (cg-RX-API-DMAC7.html) 2006-10-02
EP0804237B1 (en) 2006-07-26
EP0804237B8 (en) 2006-11-08
AU1696095A (en) 1995-08-08
KR100367948B1 (ko) 2003-07-12
CN1140413A (zh) 1997-01-15
EP0804237A1 (en) 1997-11-05
KR970700513A (ko) 1997-02-12
AU703152B2 (en) 1999-03-18
JPH09508272A (ja) 1997-08-26
EP0804237A4 (en) 2003-04-16
JP2013165718A (ja) 2013-08-29
HU220799B1 (hu) 2002-05-28
NO319867B1 (no) 2005-09-26
DE69535133T2 (de) 2008-08-21
NO963097L (no) 1996-09-24
LU91271I2 (fr) 2006-10-02
FR06C0024I2 (fr) 2009-01-02
JP2009235078A (ja) 2009-10-15
ES2270425T3 (es) 2007-04-01
HUT75129A (en) 1997-04-28
PL315634A1 (en) 1996-11-25
PT804237E (pt) 2006-10-31
ES2424292T3 (es) 2013-09-30
JP2013173738A (ja) 2013-09-05
JP4115517B2 (ja) 2008-07-09
FR06C0024I1 (cg-RX-API-DMAC7.html) 2006-10-13
NL300238I2 (nl) 2007-05-01
WO1995019790A1 (en) 1995-07-27
DK0804237T3 (da) 2006-10-16
NO963097D0 (no) 1996-07-24
FI962958A0 (fi) 1996-07-24
JP2006045237A (ja) 2006-02-16
NO2017040I1 (no) 2017-08-01
DK1759709T3 (da) 2013-06-10
CA2182013C (en) 2007-07-17
CA2182013A1 (en) 1995-07-27
PL181827B1 (pl) 2001-09-28

Similar Documents

Publication Publication Date Title
ATE333895T1 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
DE69433406T2 (de) Antikörper gegen cd40
ATE477273T1 (de) Humanisierte antikoerper gegen gamma-interferon
MY154009A (en) Anti-alpha v beta 6 antibodies
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE3586536D1 (de) Monoklonaler antikoerper gegen ein cytotoxin, denselben erzeugendes hybridoma und verfahren fuer die herstellung des gereinigten cytotoxin.
NL300163I1 (nl) Vermenselijkte anti-CD1 11a-antilichamen.
DE69128543D1 (de) Monoklonale antikörper der maus
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
DE3482905D1 (de) Monoklonale antikoerper gegen lungenkrebs des "nicht-kleine-zellen"-typs.
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
DE69601154D1 (de) Zubereitungen für die Behandlung von Hepatitis C
NO970463D0 (no) Påföringsbånd for rörledning, uten "primer"
FR2716346B3 (fr) Gant de ponçage.